Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.56 |
| ▸ | PGR | P06401 | 8/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859774 | 0.72 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL23567196 | 0.71 | MEN1 (0.49) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL31281560 | 0.71 | MEN1 (0.49) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL31955647 | 0.71 | MCL1 (1.00) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL592629 | 0.71 | MCL1 (1.00) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL592396 | 0.71 | MCL1 (0.59) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL5231375 | 0.71 | AR (0.75) | ARPGRNR3C2MCL1ATM | |
| SCHEMBL20777005 | 0.70 | CASP1 (0.59) | ARPGRNR3C2MCL1HSD17B3 | |
| SCHEMBL12611304 | 0.69 | ALDH1A1 (0.67) | ARMCL1HSD17B3KDM4EMEN1 | |
| SCHEMBL236736 | 0.69 | AR (0.74) | ARHSD17B3KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884820-B2 | 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | TPO, TTR, FABP1 | AR 2046/4885PGR 3385/4885NR3C2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.